Cargando…

Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study

BACKGROUND: Subcutaneous tocilizumab (TCZ SC) is approved globally for giant cell arteritis (GCA). This phase Ib study investigated the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of intravenous (IV) TCZ 6 and 7 mg/kg in patients with GCA. This study explored an IV dose resu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmitt, Christophe, Brockwell, Laura, Giraudon, Mylène, Zucchetto, Mauro, Christ, Lisa, Bannert, Bettina, Daikeler, Thomas, Villiger, Peter M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166308/ https://www.ncbi.nlm.nih.gov/pubmed/35659282 http://dx.doi.org/10.1186/s13075-022-02815-9

Ejemplares similares

Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)

Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
por: Seitz, Luca, et al.
Publicado: (2021)

Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial)
por: Christ, Lisa, et al.
Publicado: (2023)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022)

Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)

Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018)

Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
por: Ohta, Ryuichi, et al.
Publicado: (2023)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series
por: Saha, Pratyasha, et al.
Publicado: (2022)

Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Publicado: (2023)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2021)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
por: Loricera, Javier, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
por: de Boysson, Hubert, et al.
Publicado: (2021)

Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
por: Hara, Kazusato, et al.
Publicado: (2021)

Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
por: Cho, Young Min, et al.
Publicado: (2023)

Tocilizumab for faster and safer remission of Takayasu’s arteritis
por: Liao, Hua, et al.
Publicado: (2022)

A Simplified PET/CT Measurement Routine with Excellent Diagnostic Accuracy for the Diagnosis of Giant Cell Arteritis
por: Imfeld, Stephan, et al.
Publicado: (2022)

Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients
por: Regola, Francesca, et al.
Publicado: (2020)

Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy
por: Venkateswaran, Niranjani, et al.
Publicado: (2020)

Takayasu arteritis: Prevalence and clinical presentation in Switzerland
por: Gloor, Andrea D., et al.
Publicado: (2021)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup
por: Cronin, Owen, et al.
Publicado: (2022)

Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
por: Mensch, Noemi, et al.
Publicado: (2023)

Throat swelling following tocilizumab infusion—not always angioedema
por: Baenziger-Sieber, Patricia, et al.
Publicado: (2021)

Giant Cell Arteritis
por: Coulier, Bruno, et al.
Publicado: (2018)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019)

Giant Cell Arteritis versus Takayasu Arteritis: An Update
por: Stamatis, Pavlos
Publicado: (2020)

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Patients’ Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study
por: Dumain, Cyril, et al.
Publicado: (2022)

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future
por: Hellmich, B., et al.
Publicado: (2020)

Specific microbiome profile in Takayasu’s arteritis and giant cell arteritis
por: Desbois, Anne Claire, et al.
Publicado: (2021)

Successful Treatment of a Patient with Giant Cell Vasculitis (Horton Arteritis) with Tocilizumab a Humanized Anti-Interleukin-6 Receptor Antibody
por: Lurati, Alfredomaria, et al.
Publicado: (2012)

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
por: Unizony, Sebastian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nn3n0fk9am3of96cnvk94n66hh